Helixmith Overview
- Year Founded
-
1996
- Status
-
Public
- Employees
-
44
- Stock Symbol
-
084990
- Investments
-
3
- Share Price
-
$2.10
- (As of Friday Closing)
Helixmith General Information
Description
Helixmith Co Ltd, formerly ViroMed Co Ltd is active in the healthcare sector in Korea. The company specializes in developing pharmaceutical products for the treatment of diseases related to peripheral artery, coronary artery, cardiovascular system and neuropathy, cancer and allergy. Its suite of products includes protein/deoxyribonucleic acid (DNA)-based biopharmaceuticals, botanical drugs and natural pharmaceuticals.
Contact Information
Website
www.helixmith.comCorporate Office
- 21, Magokjungang 8-Ro 7-Gil
- Gangseo-gu
- Seoul, 07794
- South Korea
Corporate Office
- 21, Magokjungang 8-Ro 7-Gil
- Gangseo-gu
- Seoul, 07794
- South Korea
Helixmith Timeline
Helixmith Stock Performance
As of 20-Jun-2025, Helixmith’s stock price is $2.10. Its current market cap is $96.8M with 46M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.10 | $2.07 | $1.42 - $3.66 | $96.8M | 46M | 146K | -$0.18 |
Helixmith Financials Summary
As of 31-Mar-2025, Helixmith has a trailing 12-month revenue of $3.65M.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 18,383 | 32,586 | 186,997 | 334,615 |
| Revenue | 3,647 | 3,645 | 3,214 | 2,167 |
| EBITDA | (8,283) | (10,876) | (42,967) | (25,371) |
| Net Income | (8,345) | (11,339) | (49,018) | (33,695) |
| Total Assets | 100,040 | 101,081 | 176,366 | 201,172 |
| Total Debt | 165 | 143 | 15,696 | 16,288 |
Helixmith Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Helixmith Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Helixmith Patents
Helixmith Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4516913-A1 | Aav vector optimized for intrathecal administration into which hepatocyte growth factor gene is introduced | Pending | 27-Apr-2022 | ||
| EP-4501312-A1 | Liquid formulation pharmaceutical composition comprising plasmid dna | Pending | 24-Mar-2022 | ||
| US-20220362298-A1 | Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof | Pending | 26-Sep-2019 | ||
| EP-4039703-A1 | Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof | Pending | 26-Sep-2019 | ||
| EP-4039703-A4 | Chimeric antigen receptor comprising anti c-met antibody or antigen binding fragment thereof, and use thereof | Pending | 26-Sep-2019 | C07K14/70521 |
Helixmith Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Helixmith Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Helixmith Investments & Acquisitions (3)
Helixmith’s most recent deal was a Corporate Asset Purchase with Vical (DNA Production Facility). The deal was made on 20-Aug-2018.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Vical (DNA Production Facility) | 20-Aug-2018 | Corporate Asset Purchase | Buildings and Property | ||
| Wacker Biotech US | 01-Aug-2018 | Joint Venture | BPO/Outsource Services | ||
| Helixir (Drug Discovery) | 10-Nov-2009 | Merger/Acquisition | Pharmaceuticals |
Helixmith ESG
Risk Overview
Risk Rating
Updated September, 15, 2023
30.34 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,673
Rank
Percentile
Pharmaceuticals
Industry
of 844
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
Helixmith Exits (1)
Helixmith’s most recent exit was on 01-Aug-2018 from Wacker Biotech US. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Wacker Biotech US | 01-Aug-2018 | Completed |
|
Helixmith FAQs
-
When was Helixmith founded?
Helixmith was founded in 1996.
-
Where is Helixmith headquartered?
Helixmith is headquartered in Seoul, South Korea.
-
What is the size of Helixmith?
Helixmith has 44 total employees.
-
What industry is Helixmith in?
Helixmith’s primary industry is Biotechnology.
-
Is Helixmith a private or public company?
Helixmith is a Public company.
-
What is Helixmith’s stock symbol?
The ticker symbol for Helixmith is 084990.
-
What is the current stock price of Helixmith?
As of 20-Jun-2025 the stock price of Helixmith is $2.10.
-
What is the current market cap of Helixmith?
The current market capitalization of Helixmith is $96.8M.
-
What is Helixmith’s current revenue?
The trailing twelve month revenue for Helixmith is $3.65M.
-
What is Helixmith’s annual earnings per share (EPS)?
Helixmith’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
